Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CTX310 · 1 trial · 10 indications
Incidence of dose-limiting toxicities and frequency of adverse events
| Arm | Type | Description |
|---|---|---|
| CTX310 | EXPERIMENTAL | Subjects will receive an intravenous (IV) infusion. |
| Name | Type | Description |
|---|---|---|
| CTX310 | DRUG | CTX310 is a lipid nanoparticle (LNP) formulation of clustered regularly interspaced short palindromic repeats (CRISPR)-associated protein 9 (Cas9) components for in vivo editing of the target gene angiopoietin-like 3 (ANGPTL3). |
Key Inclusion Criteria: 1. Age of ≥18 and ≤75 years at the time of signing the informed consent. 2. Able to provide written informed consent. 3. Participants diagnosed with persistent dyslipidemias defined by TG ≥150 mg/dL - and LDL-C ≥70 mg/dL in participants with ASCVD, or LDL-C ≥70 or 100mg/dL i...
CTX310 is an investigational small molecule being developed for cardiovascular and metabolic conditions, specifically refractory dyslipidemias. It is being studied in participants with lipid disorders including hypertriglyceridemia, heterozygous and homozygous familial hypercholesterolemia, severe hypertriglyceridemia, mixed hyperlipemia, and hypercholesterolaemia.
CTX310 targets ANGPTL3, a protein involved in lipid metabolism. By targeting ANGPTL3, the drug is being evaluated for its potential to address refractory dyslipidemias, which are characterized by abnormal levels of lipids in the blood.
CTX310 is being developed by CRISPR Therapeutics AG, a biopharmaceutical company traded on the stock exchange under the ticker CRSP. The company is conducting clinical research to evaluate the safety and tolerability of CTX310 in patients with refractory dyslipidemias.
CTX310 is currently in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still being studied in clinical trials to assess its safety and tolerability in humans.
CTX310 is being evaluated in a Phase 1 clinical trial with the identifier NCT07491172. This trial is titled 'A Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory Dyslipidemias' and is currently recruiting participants. The trial is an uncontrolled, open-label study enrolling approximately 90 participants.
The Phase 1 clinical trial of CTX310 is being conducted in multiple countries, including the United States, Australia, New Zealand, and the United Kingdom. The trial enrolls adults aged 18 years and older, and it is open to all sexes. The study does not include healthy volunteers.